chrisvoncsefalvay/vaers-outcomes huggingface dataset:
8/21/15- Influenza injection given in rt. shoulder, I knew immediately that it was given too high (I am a nurse). Injection stung as given, shoulder became very sore, stiff and movements (especially crossing midline) became very painful over the course of next few days, interfering with sleep and ADL. Took Aleve, kept thinking it would improve.  When it did not, I emailed Dr. to notify her and ask for direction. She referred me to orthopedic MD with shoulder specialty. Appointment was 9/21/15. Exam and Xray done. Xray was not significant. Exam significant for rotator cuff type injury, cortisone injection given and PT prescribed. Significant relief after cortisone injection. Went to PT x 5 sessions. Felt better, some continued discomfort with movements over midline, but able to sleep and do most activities with little/no discomfort. 12/10/2015 - Return of shoulder discomfort symptoms. Notified Dr. and orthopedic. Saw orthopedic. Symptoms present as noted above. PT prescribed x 3 with recommendation to return if not significant improvement after 3 PT. Return to orthopedic 2/2/16 after no significant improvement from PT. Recommendation for MRI with contrast. 2/8/2016 MRI with contrast done, right shoulder. 2/12/2016 Received call from orthopedic. Orthopedic reported that MRI showed "some significant tears in rotator cuff". Orthopedic recommended referral to shoulder surgeon. This appointment has not been scheduled as of yet. Awaiting phone call from this office.
Onset of symptoms on 5/1/00 at 19:30 with headache, fever and chills, numbness in upper extremities, tingling in fingers, whole body ached and had joint pains, diarrhea, fatigue, restlessness and dizziness.
pt recv vax;spit up a lot & made sounds & became limp;given Motrin;pt's face was pale;mom shook her;sx lasted for 15 min per mom;
Pt started with low grade fevers on 7/2 and those continued through midday 7/5. After her fevers stopped she broke out in a while body rash, which looks like a roseolla.  Her twin sister did not have any of these symptoms.
FEVER; CHILLS; This spontaneous report received from a patient concerned a 48 year old male. The patient's height, and weight were not reported. The patient's concurrent conditions included non smoker, and alcohol user, and other pre-existing medical conditions included the patient had no known allergies and had no drug abuse or illicit drug usage.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unk) dose was not reported, administered on 09-APR-2021 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On 09-APR-2021, the subject experienced chills. On 09-APR-2021 18:00, the subject experienced fever. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from fever, and chills. This report was non-serious.
Big, red, pink lump; Itchy; Big, red, pink lump; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PRURITUS (Itchy), VACCINATION SITE INDURATION (Big, red, pink lump) and VACCINATION SITE ERYTHEMA (Big, red, pink lump) in an 81-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 032L20A) for COVID-19 vaccination.     No Medical History information was reported.   On 25-Jan-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE PRURITUS (Itchy), VACCINATION SITE INDURATION (Big, red, pink lump) and VACCINATION SITE ERYTHEMA (Big, red, pink lump). At the time of the report, VACCINATION SITE PRURITUS (Itchy), VACCINATION SITE INDURATION (Big, red, pink lump) and VACCINATION SITE ERYTHEMA (Big, red, pink lump) outcome was unknown.            No concomitant medications were reported.  No treatment medications were reported.  Action taken with mRNA-1273 in response to the events was not applicable
Mom brought child to have TST check on 7/16/10. Pt was last seen on 7/14/10 in which visit, she got PENTACEL and PCV13. On 7/16, pt was having some swelling bil. with redness and worse on LD than RD. Advised mom to put ice QID to decrease swelling.
pt recvd 2 doses of vax & lab eval 6-7wks post vax revealed 11 neg titers & 6 equivocal titers;1 of these pts also devel lesions;nurse reported another pt who also devel lesions;
Vague muscle discomfort/weakness in legs, arms, and back.  Continued symptoms this morning, (12/04/2013).
as you get older you wake up with a different malady; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP), Program ID. The reporter is the patient.  A patient (no qualifiers provided) received rsv vaccine prot.subunit pref 2v (ABRYSVO), as dose number unknown, single (Batch/Lot number: unknown) for immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: MALAISE (non-serious), outcome "unknown", described as "as you get older you wake up with a different malady".  The information on the batch/lot number for RSV VACCINE PROT.SUBUNIT PREF 2V has been requested and will be submitted if and when received.
16June2014: Rash on upper torso of 5 days duration. 18June2014: Varicella zoster PCP. Positive (Result 19Jun14). 18June2014: Thrombophilia and findings consistent with Autoimmune Homolytic Anemia with suppressed marrow response.
Left deltoid .6cm x .3cm blister area where injection was given (Noted 10/26/06 by home care aide)
No adverse reaction occurred.  Pt. was 17 years if age when she inadvertently received the  Moderna vaccine 1st dose
During the 15 minute observation period post vaccination,  developed itching, small red bumps on both upper arms, slight redness across chest.  Vital Signs stable, no shortness of breath.  Advised to obtain an antihistamine such as Benadryl and take according to package directions.  Was with grandfather who was driving.  Kept at observation site and additional 15 minutes.  Advised to call primary physician or go to emergency room is symptoms do not resolve or become worse.
One day, post vax, pt developed a rash on her face and legs of little, fine bumps. The rash on her face began to disappear after 1 week.
facial hives, left arm numbness and tingling, facial flushing w/  parenthesis. Evaluated by EMS-Cleared
painful menstrual cycle. The period came two days early with abnormal headaches, cramps, and back pain.
pt recv vax APR96 & devel an inj site rxn, characterized by redness, swelling  & tenderness;
Information has been received from a registered nurse concerning a 64 year old male patient with history of "immunosuppression of unspecified etiology" who on 04-MAR-2010 was vaccinated intramuscularly with his first 0.5 ml dose of PNEUMOVAX 23 (Lot # 664537/1193Y). It was reported that one day after receiving the PNEUMOVAX 23, on 05-MAR-2010, the patient experienced an injection site reaction, she was seen at the office exhibiting redness, swelling and severe pain at the injection site and down the arm. No treatment was prescribed. The patient recovered on an unspecified date. No diagnostic tests were performed. The report is related with WAES # 1003USA00920, WAES # 1003USA00981, WAES # 1003USA00982 and WAES # 1003USA00983, same source, same adverse experience. Additional information has been requested.
redness; pain; swelling at the site; little fatigue; This case was reported by a consumer via other manufacturer and described the occurrence of erythema in a 82-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Concurrent medical conditions included shellfish allergy and iodine allergy (also to contrast dye).   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced erythema, pain, injection site swelling and fatigue. On an unknown date, the outcome of the erythema, pain, injection site swelling and fatigue were recovered/resolved.   It was unknown if the reporter considered the erythema, pain, injection site swelling and fatigue to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient had allergy to shellfish, iodine and contrast dye. The reporter stated that, after Shingrix vaccination, had redness, pain injection site swelling and fatigue. The reporter stated that, in a couple of days back to herself.
This spontaneous report was received from a nurse concerning a patient of unknown gender and age. On 18-MAY-2015 the patient was vaccinated with an improperly stored dose of GARDASIL (lot # K006960; expiration date: 19-FEB-2017) (dose and route not provided). No adverse effects were reported. This is one of several reports received from the same source. Additional information has been requested.
Information has been received from al licensed practical nurse concerning 5 female patient's, all over 60 years old with some 70 to 80 years old, all with medical history, who in 2003 were each vaccinated with a dose of pneumococcal 23v polysaccharide vaccine (lot # 647681/0986N). All of the patients had concomitant medications. At least two of the patient's received a prior dose of pneumococcal 23v polysaccharide vaccine. Subsequently in 2003, the patient's developed injection site reactions the size of a saucer that were red and inflamed. Unspecified medical attention was sought. Subsequently, all of the patients fully recovered. A product quality complaint was not involved. The reporter stated the doctor was concerned because all patients received the same lot number. The records of testing prior to release of this lot have been checked and found to be satisfactory. The lot complies with the standards and was released. One of the female patients had a larger injection site reaction that also included blisters. This patient was treated with sulfamethoxazole (+) trimethoprim bid for seven days. Follow up information received from the licensed practical nurse concerning the female patient treated with sulfamethoxazole (+) trimethoprim. The patient was an 86 year old Caucasian female patient with COPD, HTN, anemia, hypothyroidism and PVD who on 11/19/03 at 13:00 was vaccinated IM in the left deltoid with a second dose of pneumococcal 23v polysaccharide vaccine (lot # 647681/0986N). There was no illness at the time of vaccination. On 11/20/03 at 15:45, the patient developed red, swollen, cellulitis and was treated with sulfamethoxazole (+) trimethoprim. On 1/1/04, the patient died from congested heart failure. Cellulitis was considered to be an other important medical event (OMIC). One of the other female patients was treated with cephalexin. Another one of the female patient received no treatment. The remaining two female patients were treated with diphenhydramine hydrochloride and cold packs. Additional information is not expected. The hospital discharge summary received on 2/18/04 states influenza, fever, respiraotry distress, and altered mental status.
The caller has not received a 2nd dose and it is beyond 35 days after 1st dose; This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (The caller has not received a 2nd dose and it is beyond 35 days after 1st dose) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 31-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (The caller has not received a 2nd dose and it is beyond 35 days after 1st dose). At the time of the report, PRODUCT DOSE OMISSION ISSUE (The caller has not received a 2nd dose and it is beyond 35 days after 1st dose) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported. No treatment details were reported.
hives on face, upper arms & abd 15min p/vax;no resp distress noted;pulse strong & regular;alert & oriented;no tx necessary;hives began to subside by 245-3PM when dad picked child up;
PATIENT WAS FEELING LIGHTHEADED WITHIN MOMENTS OF RECEIVING VACCINE. WITHIN A FEW MINUTES, THE PATIENT WAS SWEATY, NAUSEATED, AND STATED SHE FELT LIKE SHE WAS "GOING TO THROW UP AND/OR PASS OUT".  AFTER ABOUT 10 MINUTES, SHE WAS FEELING MUCH BETTER.
This spontaneous report was received from a physician, via company representative, and refers to a patient of unknown age and gender. Pertinent medical history, concurrent conditions, drug reactions or allergies and concomitant therapies were not reported. On 14-DEC-2015, the patient was vaccinated with a dose of PNEUMOVAX 23 10 PK-0.5 ml SD-PFS LLokwTip, lot # L002310, expiration date 08-JUL-2016, (route and anatomical location of administration were unspecified) which was improperly stored in refrigerator to a temperature excursion of 1.1 Celsius degrees for 208 hours with lowest temperature recorded of 34 Fahrenheit degrees. No adverse effects were reported and no product quality complaint (PQC) was involved. This is one of several reports received from the same reporter. Additional information has been requested.
Shoulder pain following injection that did not improve.  Noticed extreme shoulder pain when reaching behind back 2 days after injection.
Disequilibrium, trouble reading and concentrating, lightheadedness and heart palpitations. Noticed in the afternoon while working at computer.  I had to stop work and rest until symptoms eased about 2 hours later.  These same symptoms repeated for several days before stopping.  I have never had these symptoms before the vaccine.
FATIGUE, FEVER OF GREATER THAN 101.5 FOR APPROX 9 HOURS, CHILLS, MUSCLE WEAKNESS
seizure; couldn't move and speak; couldn't move and speak; chills; This is a spontaneous report from a contactable consumer.  A female patient of an unspecified age (age: 77, unit: unknown) received the first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE; lot number and expiry date not reported), via an unspecified route of administration on 24Feb2021 at single dose for covid-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient experienced seizure, couldn't move and speak and chills on 26Feb2021. The patient received first dose of Pfizer on 24Feb2021, and experienced a seizure 48 hours later.  She was experiencing severe chills, then during the night, woke up with a seizure, couldn't move and speak, didn't go to the ER, no history of seizure, already filed safety report. She wants to know if she can receive the second vaccine. The outcome of the events was unknown.   Information on the Lot/Batch number has been requested.
Pt stated that she had a red, rash on her upper thigh. She stated that it was not itchy. Pt told to take antihistamine, use cold compress or carefully put anti-itch cream if the rash got worse.
super sick since second dose; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of ILLNESS (super sick since second dose) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. unknown) for COVID-19 vaccination.     No Medical History information was reported.    On 24-May-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 24-May-2021, the patient experienced ILLNESS (super sick since second dose). At the time of the report, ILLNESS (super sick since second dose) outcome was unknown.            No concomitant and treatment information provided.    AE submitted via chatbot I got my second shot (maderna) on Monday.. I've been super sick ever since. What can I do?
This spontaneous report as received from a healthcare worker refers to a 4 year old patient of unknown gender. Concurrent conditions and medical history were not reported. On 18-SEP-2015, the patient was vaccinated with an improperly stored PROQUAD (Merck) (lot number L010142 expiration date 24-SEP-2016, therapy type, dose and route of administration were not provided). Concomitant therapy was not reported. No adverse effects were reported. This is one of several reports from the same source. Additional information has been requested.
Itching at injection site; Rash and redness at the injection site; Under armpit swollen; rash and redness at the injection site; A spontaneous report was received from a consumer, concerning herself, a female patient of unspecified age, who received Moderna's COVID-19 vaccine and experienced itching at the injection site, rash and redness at the injection site and under armpit swollen.   The patient's medical history was not provided. Concomitant product use was not provided by the reporter.  On 12-Jan-2021, prior to the onset of events, the patient received the first of two planned doses of mRNA-1273 (lot number unknown) intramuscularly for prophylaxis of COVID-19 infection.   On an unspecified date in Jan-2021, after the shot of vaccine on tuesday, the patient experienced rash and redness at the injection site, which had gone away. However, on an unspecified date in Jan-2021, additionally the patient developed itching at the injection site and under armpit was also swollen. Treatment information was not provided.  Action taken with mRNA-1273 in response to events were not reported.  The outcome of events, rash and redness at the injection site was considered resolved on an unspecified date in Jan-2021. The outcome of events, itching at the injection site and under armpit swollen was considered unknown. Reporter's Comments: This case concerns a female patient,  who experienced  a non-serious unexpected event of injection site pruritus, and non-serious expected events of  injection site rash and injection site erythema and lymphadenopathy. The events of injection site pruritus, injection site rash, injection site erythema, and lymphadenopathy occurred after first dose of mRNA-1273, COVID-19 vaccine . Based on the current available information and temporal association between the use of the product and onset of the events , a causal relationship cannot be excluded.
shingles; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of HERPES ZOSTER (shingles) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced HERPES ZOSTER (shingles). At the time of the report, HERPES ZOSTER (shingles) outcome was unknown.            Within a week after second vaccine shot patient developed shingles. No concomitant medications were mentioned. No treatment details were reported.   Reporter did not allow further contact
Initial report was received on 21/Sep/2012 from a 34 year old patient. Medical history and concomitant medications were not reported. The patient received FLUZONE, lot # UH711AA, dose and expiry not reported, IM in the left arm. The patient reported being vaccinated previously with FLUZONE, but dates and details were not reported. The patient developed itchy, red bumps on legs, arms, neck, face, torso, top of foot as well as headaches and dizziness 8 or 9 days post vaccination. The patient was seen by a physician and was treated with ATARAX which according to the patient, relieved signs and symptoms for the first day, but the itching continues. The patient was diagnosed with folliculitis. The patient's outcome was reported as unknown. Documents held by sender: none.
TMJ disorder lasting about 6 weeks, couldn?t open my mouth for two days.  Throbbing painful tooth that had a crown put on lasting about 4 weeks.  Diminished hand/eye coordination (duration unknown).  Inability to process information after reading (duration unknown)  Bilateral tinnitus (ongoing since second dose)  Diminished motivation and decrease in physical strength (ongoing)
Fever was 100.6; Myalgias; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP).  A 10 year-old female patient received bnt162b2 (BNT162B2), administration date 28Nov2021 (Batch/Lot number: unknown) as dose 2, single for covid-19 immunisation. The patient had no relevant medical history. The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose 1, Received the  10mcg dose), administration date: 07Nov2021, for COVID-19 immunization, reaction(s): "without any reactions". The following information was reported: PYREXIA (non-serious) with onset 29Nov2021, outcome "unknown", described as "Fever was 100.6"; MYALGIA (non-serious) with onset 29Nov2021, outcome "unknown", described as "Myalgias". Relevant laboratory tests and procedures are available in the appropriate section.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Lump (i.e. hive) present on arm.  Stiff neck on left side. Chest pain presented that same night and concerned her enough to take a Bayer aspirin tablet.
Initial report was received 11 August 2008 from another manufacturer who received the report from a health care professional.  A patient (age and gender not reported) experienced an anaphylactic reaction after receiving a flu vaccination (manufacturer, lot number, route and site not reported).  No further information pertaining to the event or patient's recovery status were provided at the time of the report.
patient is here to get his 2nd dose / has been 1.5 years since 1st dose; This case was reported by a pharmacist and described the occurrence of incomplete course of vaccination in a 59-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st dose of Shingrix 1.5 years prior to reporting).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.  Additional details were provided as follows: The age at vaccination was not applicable for this report. Till the time of reporting, patient did not received 2nd dose of Shingrix, which led to incomplete course of vaccination. No vaccine details, lot and expiration date were provided. The VAERS details for 1st dose were updated. The reporter asked if it was too late. The reporter consented to follow up.
I work at Medical Center and my job required I get the MMR shot even though I had measles as a child. I received the shot at a clinic that was set up for people who needed to get one. By that afternoon after I had recieved the shot my heart was beating irregularly, I was wheezing and coughing. I had some dizziness at work yesterday but just for a short time. I am still wheezing(mostly at night) and coughing all day and night long. I went to the ER at Medical Center today (5-10-08) and the ER doctor gave me a prescription for an Albuteral Inhaler. My breathing and everthing else was fine before I received the shot.